199 related articles for article (PubMed ID: 34107196)
1. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Mehta J
N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107196
[No Abstract] [Full Text] [Related]
2. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Meisel R
N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107195
[No Abstract] [Full Text] [Related]
3. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.
Frangoul H; Ho TW; Corbacioglu S
N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107197
[No Abstract] [Full Text] [Related]
4. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
Parums DV
Med Sci Monit; 2024 Mar; 30():e944204. PubMed ID: 38425279
[TBL] [Abstract][Full Text] [Related]
5. Treatment by CRISPR-Cas9 Gene Editing - A Proof of Principle.
Malech HL
N Engl J Med; 2021 Jan; 384(3):286-287. PubMed ID: 33471982
[No Abstract] [Full Text] [Related]
6. CRISPR in personalized medicine: Industry perspectives in gene editing.
Hong A
Semin Perinatol; 2018 Dec; 42(8):501-507. PubMed ID: 30376985
[TBL] [Abstract][Full Text] [Related]
7. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
8. Promising Strategies for Sickle Cell Disease and β-Thalassemia.
Abbasi J
JAMA; 2021 Jan; 325(2):121. PubMed ID: 33433564
[No Abstract] [Full Text] [Related]
9. CRISPR gene therapy shows promise against blood diseases.
Ledford H
Nature; 2020 Dec; 588(7838):383. PubMed ID: 33299166
[No Abstract] [Full Text] [Related]
10. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
Harris E
JAMA; 2024 Jan; 331(4):280. PubMed ID: 38170544
[No Abstract] [Full Text] [Related]
11. Discontinued CRISPR gene therapy for sickle-cell disease improves symptoms.
Carvalho T
Nat Med; 2023 Nov; 29(11):2669-2670. PubMed ID: 37783810
[No Abstract] [Full Text] [Related]
12. Tweaking genes with CRISPR or viruses fixes blood disorders.
Kaiser J
Science; 2020 Dec; 370(6522):1254-1255. PubMed ID: 33303593
[No Abstract] [Full Text] [Related]
13. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
14. [Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology].
Bao LW; Zhou YY; Zeng FY
Yi Chuan; 2020 Oct; 42(10):949-964. PubMed ID: 33229321
[TBL] [Abstract][Full Text] [Related]
15. UK first to approve CRISPR treatment for diseases: what you need to know.
Wong C
Nature; 2023 Nov; 623(7988):676-677. PubMed ID: 37974039
[No Abstract] [Full Text] [Related]
16. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
Elife; 2022 Feb; 11():. PubMed ID: 35147495
[TBL] [Abstract][Full Text] [Related]
17. The Cas9 Hammer-and Sickle: A Challenge for Genome Editors.
Urnov FD
CRISPR J; 2021 Feb; 4(1):6-13. PubMed ID: 33616446
[TBL] [Abstract][Full Text] [Related]
18. Rationally Designed Base Editors for Precise Editing of the Sickle Cell Disease Mutation.
Chu SH; Packer M; Rees H; Lam D; Yu Y; Marshall J; Cheng LI; Lam D; Olins J; Ran FA; Liquori A; Gantzer B; Decker J; Born D; Barrera L; Hartigan A; Gaudelli N; Ciaramella G; Slaymaker IM
CRISPR J; 2021 Apr; 4(2):169-177. PubMed ID: 33876959
[TBL] [Abstract][Full Text] [Related]
19. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
